Surgical outcomes and immunohistochemical features for gastrointestinal stomal tumors (GISTs) of the stomach: With special reference to prognostic factors

Sungsoo Park, Je Seock Ryu, Seung Yeop Oh, Wan-Bae Kim, Ju-Han Lee, Yang Seok Chae, Seung Joo Kim, Chong Suk Kim, Young Jae Mok

Research output: Contribution to journalArticle

9 Citations (Scopus)


Background/Aims: Stomach is the most common site of gastrointestinal stromal tumors (GISTs). But the preoperative pathologic diagnosis is often difficult to make and it is hard to decide an appropriate surgical extent and also adjuvant therapy due to obscure malignant potential. Our purpose was to observe the outcomes for the patients with GIST of the stomach and reveal the significant prognostic factors. Methodology: Forty patients operated for primary GIST of the stomach expressing CD117 were studied. We evaluated immunohistochemical and clinicopathologic features, and analyzed them to reveal the significant prognostic factors. The surgical outcomes of the patients were also investigated. Results: Multivariate analysis for disease-free survival disclosed mitotic activity was the only independent factor, but the immunohistochemical features did not have any prognostic value. Among the patients with recurrence, all of the patients treated with imatinib mesylate (formerly STI-571) have survived until now, but half of the untreated patients died. Conclusions: In gastric GISTs, most important prognostic factor is mitotic count, not tumor size. We suggest that the wider application of imatinib mesylate to clinically malignant gastric GIST as adjuvant therapy may contribute to the improvement of outcomes.

Original languageEnglish
Pages (from-to)1454-1457
Number of pages4
Issue number77
Publication statusPublished - 2007 Jul 1



  • Gastrointestinal stromal tumor
  • Prognosis
  • Stomach
  • Surgical outcome

ASJC Scopus subject areas

  • Medicine(all)
  • Hepatology
  • Gastroenterology

Cite this